SCHEMBL1329916

SCHEMBL1329916

ICc1cccc(Oc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 4/20 0.50
HTT P42858 2/20 0.50
TSHR P16473 2/20 0.50
LTA4H P09960 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
HPGD P15428 1/20 0.50
MAOB P27338 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CETP P11597 1/20 0.46
AKR1C3 P42330 1/20 0.46
FFAR1 O14842 2/20 0.45
TRPV6 Q9H1D0 1/20 0.45
FDFT1 P37268 1/20 0.45
FFAR4 Q5NUL3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15565006 0.84 ALDH1A1 (0.58) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL473301 0.83 KDM4E (0.50) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL8896665 0.83 TSHR (0.55) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL416807 0.81 FDFT1 (0.51) FFAR1FDFT1
SCHEMBL14319102 0.80 LTA4H (0.61) TSHRLTA4HFFAR1
SCHEMBL23312282 0.79 ALDH1A1 (0.50) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL358425 0.79 LTA4H (0.67) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL11090830 0.79 KDM4E (0.50) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL8353925 0.79 IDO1 (0.52) KDM4EALDH1A1HTTTSHRLTA4H
SCHEMBL1218850 0.79 KDM4E (0.50) KDM4EALDH1A1HTTTSHRLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507815-B2 Succinoylamino lactams as inhibitors of a-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-24 US claimed
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 US claimed
EP-0161827-A1 Novel intermediate for the preparation of cyclopropane carboxylate esters and its preparation and use INDIAN EXPLOSIVES LIMITED (IN) 1985-11-21 EP claimed
CN-118076767-A Method and formulation for producing an optical metal oxide layer 默克专利有限公司 2024-05-24 CN disclosed
WO-2023057401-A1 METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS MERCK PATENT GMBH (DE) 2023-04-13 WO disclosed
CN-101193908-B Organic compounds NOVARTIS AG 2012-04-11 CN disclosed
US-20110281845-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-11-17 US disclosed
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 US disclosed
US-7507815-B2 Succinoylamino lactams as inhibitors of a-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-24 US disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 US disclosed
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 US disclosed
US-20020159947-A1 Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging LANTHEUS MEDICAL IMAGING, INC. 2002-10-31 US disclosed
US-6331408-B1 CONTACTING A POTENTIAL INHIBITOR OF BETA-AMYLOID PRODUCTION AND TAGGED INHIBITOR OF BETA-AMYLOID PRODUCTION WITH AT MACROMOLECULE INVOLVED IN PROCESSING OF AMYLOID PRECURSOR PROTEIN; SEPARATING TAGGED INHIBITOR, DETERMINING BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-12-18 US disclosed
WO-2001087354-A2 USE OF SMALL MOLECULE RADIOLIGANDS FOR DIAGNOSTIC IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-11-22 WO disclosed
EP-1129355-A1 USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION Du Pont Pharmaceuticals Company (US) 2001-09-05 EP disclosed
CN-1311779-A Succinoylamino lactams as inhibitors and as A beta protein production DU PONT PHARM CO (US) 2001-09-05 CN disclosed
EP-1102752-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION Du Pont Pharmaceuticals Company (US) 2001-05-30 EP disclosed
WO-2000028331-A1 USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2000-05-18 WO disclosed
WO-2000007995-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2000-02-17 WO disclosed
EP-0161827-A1 Novel intermediate for the preparation of cyclopropane carboxylate esters and its preparation and use INDIAN EXPLOSIVES LIMITED (IN) 1985-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069294-A1 Organic Compounds XIAP, BAX, MCL1 KDM4E 2903/4885ALDH1A1 1673/4885HTT 2950/4885
US-20110281845-A1 ORGANIC COMPOUNDS XIAP, BAX, MCL1 KDM4E 2898/4885ALDH1A1 1672/4885HTT 2950/4885
US-20020159947-A1 Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging APP, BACE1, BACE2 KDM4E 4802/4885ALDH1A1 4470/4885HTT 58/4885
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BACE1, APH1A, APP KDM4E 3215/4885ALDH1A1 2329/4885HTT 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.